Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | Mr. Dion J. WeislerIndependent Director | -80,29 | 36,27k | Sale to Issuer | 451,79 | 4,95k | -1,60% |
| 2026-04-27 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400,00 | 185,06k | Automatic Disposition | 462,66 | 25,05k | -1,57% |
| 2026-03-11 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -1,61k | 802,54k | Automatic Disposition | 499,40 | 18,32k | -8,06% |
| 2026-03-05 | Mr. Marc N. CasperChairman & CEO | -4,00k | 820,74k | Derivative Exercise and Sale | 309,63 - 519,74 | 141,91k | - |
| 2026-03-03 | Mr. Marc N. CasperChairman & CEO | -10,00k | 1,98M | Derivative Exercise and Sale | 309,63 - 516,75 | 141,91k | - |
| 2026-02-28 | Mr. Marc N. CasperChairman & CEO | -4,68k | 2,44M | Sale to Issuer | 521,11 | 141,91k | -3,20% |
| 2026-02-28 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -348,08 | 181,39k | Sale to Issuer | 521,11 | 13,33k | -2,54% |
| 2026-02-28 | Mr. Joseph R. HolmesVP & CAO | -116,63 | 60,77k | Sale to Issuer | 521,11 | 2,52k | -4,42% |
| 2026-02-28 | Mr. Michel LagardeInitié | -1,20k | 623,56k | Sale to Issuer | 521,11 | 85,15k | -1,39% |
| 2026-02-28 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -1,07k | 559,35k | Sale to Issuer | 521,11 | 25,45k | -4,05% |
| 2026-02-28 | Mr. Stephen WilliamsonInitié | -921,79 | 480,36k | Sale to Issuer | 521,11 | 45,17k | -2,00% |
| 2026-02-28 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -815,85 | 425,15k | Sale to Issuer | 521,11 | 19,93k | -3,93% |
| 2026-02-28 | Mr. Frederick M. LoweryInitié | -896,97 | 467,42k | Sale to Issuer | 521,11 | 13,46k | -6,25% |
| 2026-02-09 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400,00 | 216,48k | Automatic Disposition | 541,20 | 20,75k | -1,89% |
| 2025-12-10 | Mr. Scott M. SperlingIndependent Lead Director | -4,39k | 0,00 | Other Disposition | - | 68,42k | -6,02% |
| 2025-12-04 | Mr. Michel LagardeInitié | 18,64k | 1,96M | Derivative Exercise and Retained Stock | 105,17 | 84,12k | 28,46% |
| 2025-12-04 | Mr. Michel LagardeInitié | -22,05k | 9,50M | Derivative Exercise and Sale | 132,66 - 563,56 | 84,12k | - |
| 2025-12-02 | Mr. Michel LagardeInitié | 42,00k | 4,42M | Derivative Exercise and Retained Stock | 105,17 | 65,48k | 178,88% |
| 2025-12-02 | Mr. Michel LagardeInitié | -62,00k | 29,61M | Derivative Exercise and Sale | 105,17 - 584,11 | 65,48k | - |
| 2025-12-02 | Mr. Thomas Bailey ShropshireSenior VP and General Counsel | -337,48 | 195,86k | Sale to Issuer | 580,37 | 5,08k | -6,23% |
| 2025-12-01 | Mr. Frederick M. LoweryInitié | -13,83k | 4,64M | Derivative Exercise and Sale | 253,99 - 597,68 | 12,19k | - |
| 2025-11-25 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -10,73k | 3,62M | Derivative Exercise and Sale | 253,99 - 600,00 | 15,57k | - |
| 2025-11-14 | Mr. Stephen WilliamsonInitié | -433,00 | 0,00 | Other Disposition | - | 44,56k | -0,96% |
| 2025-11-12 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -1,06k | 622,14k | Vente | 588,27 | 11,35k | -8,53% |
| 2025-11-13 | Mr. Michel LagardeInitié | -4,64k | 1,58M | Derivative Exercise and Sale | 253,99 - 594,42 | 23,48k | - |
| 2025-11-10 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -2,98k | 879,81k | Derivative Exercise and Sale | 253,99 - 580,00 | 21,15k | - |
| 2025-11-07 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -8,48k | 2,69M | Derivative Exercise and Sale | 253,99 - 571,67 | 12,40k | - |
| 2025-11-07 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -1,75k | 999,95k | Vente | 571,40 | 12,40k | -12,36% |
| 2025-10-24 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400,00 | 229,66k | Automatic Disposition | 574,15 | 21,15k | -1,86% |
| 2025-10-24 | Mr. Marc N. CasperChairman & CEO | -24,35k | 7,73M | Derivative Exercise and Sale | 253,99 - 575,02 | 128,85k | - |
| 2025-09-05 | Mr. Marc N. CasperChairman & CEO | -400,00 | 98,61k | Derivative Exercise and Sale | 253,99 - 501,01 | 128,85k | - |
| 2025-08-28 | Mr. Marc N. CasperChairman & CEO | -1,41k | 691,19k | Sale to Issuer | 489,74 | 128,85k | -1,08% |
| 2025-08-28 | Mr. Stephen WilliamsonInitié | -783,27 | 383,60k | Sale to Issuer | 489,74 | 44,99k | -1,71% |
| 2025-08-28 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -598,09 | 292,91k | Sale to Issuer | 489,74 | 15,57k | -3,70% |
| 2025-08-28 | Mr. Frederick M. LoweryInitié | -667,72 | 327,01k | Sale to Issuer | 489,74 | 12,19k | -5,20% |
| 2025-08-28 | Mr. Michel LagardeInitié | -961,20 | 470,74k | Sale to Issuer | 489,74 | 23,48k | -3,93% |
| 2025-08-29 | Mr. Joseph R. HolmesVP & CAO | -385,00 | 91,88k | Derivative Exercise and Sale | 253,99 - 492,63 | 1,96k | - |
| 2025-08-28 | Mr. Joseph R. HolmesVP & CAO | -36,98 | 18,11k | Sale to Issuer | 489,74 | 1,96k | -1,85% |
| 2025-08-28 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -814,70 | 398,99k | Sale to Issuer | 489,74 | 21,55k | -3,64% |
| 2025-08-28 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -328,78 | 161,02k | Sale to Issuer | 489,74 | 14,15k | -2,27% |
| 2025-08-22 | Mr. Marc N. CasperChairman & CEO | -10,00k | 2,47M | Derivative Exercise and Sale | 253,99 - 502,26 | 130,26k | - |
| 2025-08-19 | Mr. Marc N. CasperChairman & CEO | -496,00 | 122,07k | Derivative Exercise and Sale | 253,99 - 500,17 | 130,26k | - |
| 2025-08-06 | Mr. Marc N. CasperChairman & CEO | -18,00k | 3,58M | Derivative Exercise and Sale | 253,99 - 464,68 | 125,84k | - |
| 2025-07-25 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400,00 | 191,99k | Automatic Disposition | 479,98 | 22,37k | -1,76% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
